Galera Therapeutics to Participate in Fireside Chat at 2020 BTIG Virtual Biotechnology Conference
July 30 2020 - 8:00AM
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage
biopharmaceutical company focused on developing and commercializing
a pipeline of novel, proprietary therapeutics that have the
potential to transform radiotherapy in cancer, today announced that
Mel Sorensen, M.D., President and Chief Executive Officer, will
participate in an analyst-led fireside chat at the 2020 BTIG
Virtual Biotechnology Conference on Monday, August 10, 2020, at
9:30 a.m. EDT.
A live webcast of the event will be accessible from the
Investors page of Galera’s website, investors.galeratx.com. An
archived version of the webcast will be available in the News &
Events section of the Investors page of Galera’s website for 30
days following the event.
About Galera Therapeutics
Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical
company focused on developing and commercializing a pipeline of
novel, proprietary therapeutics that have the potential to
transform radiotherapy in cancer. Galera’s lead product candidate
is avasopasem manganese (GC4419), a highly selective small molecule
superoxide dismutase (SOD) mimetic initially being developed for
the reduction of radiation-induced severe oral mucositis (SOM).
Avasopasem is being studied in the Phase 3 ROMAN trial for its
ability to reduce the incidence and severity of SOM induced by
radiotherapy in patients with locally advanced head and neck
cancer, its lead indication. It is also being studied in a Phase 2a
trial for its ability to reduce the incidence of esophagitis
induced by radiotherapy in patients with lung cancer and in a pilot
Phase 1/2 trial in combination with stereotactic body radiation
therapy (SBRT) in patients with locally advanced pancreatic cancer.
The FDA granted Fast Track and Breakthrough Therapy designations to
avasopasem for the reduction of SOM induced by radiotherapy. Galera
is developing a second product candidate, GC4711, for SBRT which
successfully completed Phase 1 trials in healthy volunteers. Galera
is headquartered in Malvern, PA. For more information, please visit
www.galeratx.com.
Investor Contacts:Christopher DegnanGalera
Therapeutics, Inc.610-725-1500cdegnan@galeratx.com
Jennifer PorcelliSolebury
Trout646-378-2962jporcelli@soleburytrout.com
Media Contact:Gina Cestari6
Degrees917-797-7904gcestari@6degreespr.com
Galera Therapeutics (NASDAQ:GRTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Galera Therapeutics (NASDAQ:GRTX)
Historical Stock Chart
From Apr 2023 to Apr 2024